Edward O’Mara
Teva Pharmaceuticals (Israel)(IL)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, Hepatitis C virus research, Pharmaceutical studies and practices, HIV Research and Treatment, Antifungal resistance and susceptibility
Most-Cited Works
- → The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin*(1998)410 cited
- → The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults(2004)193 cited
- → A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers(2012)144 cited
- → Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension(2012)141 cited
- → Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers(2012)105 cited
- → Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies(2015)85 cited
- → Increased Bloodstream Infection Rates in Surgical Patients Associated with Variation from Recommended Use and Care Following Implementation of a Needleless Device(1998)80 cited
- → Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir(2012)77 cited
- → Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation*(1996)67 cited
- → Pharmacokinetics and Safety Study of Posaconazole Intravenous Solution Administered Peripherally to Healthy Subjects(2014)63 cited